![Prof. Timothy Price](https://www.basilhetzelinstitute.com.au/wp-content/uploads/2015/11/TimPrice_ASB2077-HI-026_220x220-220x220-fill-crop-constrain-q70-profile_image.jpg)
De analyse includeerde 185 bevacizumab-voorbehandelde patiënten in de panitumumab-arm en 189 bevacizumab-voorbehandelde patiënten in de cetuximab-arm. De mediane overall survival was 12,8 maanden met panitumumab versus 10,1 maanden met cetuximab (HR 0,72; p=0,0031). De mediane progressievrije overleving was 4,7 maanden met panitumumab versus 4,1 maanden met cetuximab (HR 0,79; p=0,0207). Het behandelregime was een onafhankelijke prognostische factor voor overall survival (aHR 0,69; p=0,0013).
De onderzoekers concluderen dat onder patiënten met chemotherapie-refractair KRAS wildtype mCRC die voorbehandeld waren met bevacizumab, de OS en PFS significant beter waren met panitumumab dan met cetuximab.
1.Taniguchi H, Yamanaka T, Sakai D et al. Efficacy of panitumumab and cetuximab in patients with colorectal cancer previously treated with bevacizumab; a combined analysis of individual patient data from ASPECCT and WJOG6510G. Cancers 2020;12:1715
Summary: A combined analysis of individual patient data from the ASPECCT and WJOG6510G studies found that in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer who were previously treated with bevacizumab, overall survival and progression-free survival were significantly better with panitumumab compared to cetuximab.